John McAdory

John McAdory has extensive experience leading late-stage oncology trials, including operational strategy, clinical execution, study design, and regulatory interactions. Notably, John has spent 10 years working with oncolytic virus companies and developing oncolytic virus assets across a range of tumor types in trials involving hundreds of patients.

Before joining Oncolytics in January 2026, he was Vice President, Clinical Operations at CG Oncology. Mr. McAdory’s time at CG Oncology resulted in an acceleration and expansion of the company’s clinical development pipeline. Under his leadership, the organization launched their pivotal Phase 3, which led to the company’s first BLA submission. Mr. McAdory also played a critical role in the company’s IPO in January 2024. Additionally, Mr. McAdory worked for SillaJen, first as a Senior Clinical Project Manager and then Head of Clinical Operations, where he oversaw global clinical operations spanning multiple continents, managed clinical trial budgets, and built high-performing, multidisciplinary teams.

Mr. McAdory earned a Master of Health Administration (MHA) degree focused on Public Health from the University of North Carolina at Chapel Hill and a Bachelor’s of Science (BS) Degree in Biology from Hampton University.